HOME >> MEDICINE >> NEWS
Vaxfectin-formulated measles DNA vaccine elicits long-term protection in nonhuman primates

SEATTLEMay 31, 2007Vical Incorporated (Nasdaq:VICL) today announced that a measles DNA vaccine formulated with the company's Vaxfectin adjuvant elicited protective levels of neutralizing antibodies in juvenile (1 2 year old) nonhuman primates confirmed by complete protection following challenge more than one year after vaccination, and sterilizing immunity as evidenced by no clinical signs of disease and no detectable virus after challenge. In a separate study, the same vaccine elicited protective levels of neutralizing antibodies in infant (6 10 weeks old) nonhuman primates with no vaccine-related adverse events. The studies were conducted in collaboration with Diane E. Griffin, M.D., Ph.D., Alfred and Jill Sommer Professor and Chair of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, under a grant from the Bill and Melinda Gates Foundation.

"Sterilizing immunity is a rarely achieved ultimate goal in vaccination," said Vijay B. Samant, Vical's President and Chief Executive Officer. "The ability to provide such complete immunity with no adverse events offers proof of concept for Vaxfectin-formulated DNA vaccines. We look forward to continued development of the measles vaccine program by our collaborators at Johns Hopkins."

"We have tested a number of measles DNA vaccines, and the data relating to Vical's Vaxfectin-formulated DNA vaccine showed marked differences both in terms of disease resistance after exposure and antibody levels over the other vaccines, without significant side effects," said Dr. Griffin. "These data are exciting because of the potential of providing safety and efficacy suitable for infants and young children in the developing world, and continued development could result in a major impact on global measles disease and death rates."

The study in juvenile rhesus macaques tested the protective efficacy of a bivalent DNA vaccine encoding measles hemagglutinin and fusion glycop
'"/>

Contact: Kim Richards
krichards@pnlifesciences.com
Porter Novelli, Life Sciences
31-May-2007


Page: 1 2

Related medicine news :

1. Vulnerability to measles among nursery school children risen sharply
2. New study shows measles immunization may prevent fatal brain infection
3. Traditional Chinese exercises may increase efficacy of flu vaccine
4. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
5. Study reveals gaps in vaccine financing for underinsured children
6. Trials underway for essential new TB vaccine
7. Hib vaccine: A critical ally in Asias effort to reduce child deaths
8. Progress toward an antitumor vaccine
9. Chemotherapy may enhance the effectiveness of brain tumor vaccines
10. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
11. International studies show high efficacy for HPV vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology:
Cached News: